TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Incyte Biosciences Nordic AB
Closing information (x1000 DKK)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover |
25,954
|
21,886
|
20,953 |
Financial expenses |
6
|
30
|
24 |
Earnings before taxes |
1,168
|
934
|
1,105 |
EBITDA |
1,149
|
1,032
|
1,258 |
Total assets |
8,692
|
11,211
|
11,602 |
Current assets |
7,282
|
11,135
|
11,444 |
Current liabilities |
5,247
|
8,497
|
9,251 |
Equity capital |
3,445
|
2,714
|
2,351 |
- share capital |
34
|
33
|
36 |
Employees (average) |
10
|
9
|
7 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency |
39.6%
|
24.2%
|
20.3% |
Turnover per employee |
2,595
|
2,432
|
2,993 |
Profit as a percentage of turnover |
4.5%
|
4.3%
|
5.3% |
Return on assets (ROA) |
13.5%
|
8.6%
|
9.7% |
Current ratio |
138.8%
|
131.0%
|
123.7% |
Return on equity (ROE) |
33.9%
|
34.4%
|
47.0% |
Change turnover |
3,955
|
2,630
|
5,366 |
Change turnover % |
18%
|
14%
|
34% |
Chg. No. of employees |
1
|
2
|
1 |
Chg. No. of employees % |
11%
|
29%
|
17% |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.